Management of Cystic Glandular Endometrial Hyperplasia Without Atypia Before Embryo Transfer
Treat the hyperplasia with progestins until complete regression is documented by two consecutive endometrial biopsies showing normal endometrium, then proceed immediately with assisted reproductive technology for embryo transfer to avoid recurrence from estrogen exposure.
Treatment Protocol Before Embryo Transfer
Initial Treatment Phase
For cystic glandular hyperplasia without atypia, levonorgestrel-releasing intrauterine system (LNG-IUS) is the preferred first-line treatment over oral progestins, as it achieves higher regression rates, lower recurrence rates, and fewer adverse events 1. If LNG-IUS is not feasible, oral progestins such as medroxyprogesterone acetate (MPA) are acceptable alternatives 2.
Monitoring During Treatment
- Perform ultrasound and endometrial biopsy every 6 months during treatment 1
- Continue treatment until two consecutive endometrial biopsies show no pathological changes 1
- This typically requires 6-12 months of progestin therapy
Critical Timing for Embryo Transfer
Once complete regression is confirmed, proceed immediately with IVF/embryo transfer rather than delaying, as estrogen exposure during controlled ovarian stimulation can trigger recurrence 3. The case report demonstrates successful pregnancy after conservative treatment of even atypical hyperplasia when embryo transfer was performed promptly after regression 3.
Optimal IVF Protocol Selection
Use the early-follicular long (EL) protocol rather than the midluteal long (ML) protocol for controlled ovarian stimulation. The most recent high-quality evidence shows that patients with endometrial hyperplasia using the EL protocol achieved:
- Clinical pregnancy rate of 61.8% vs 43.5% with ML protocol (P=0.032)
- Live birth rate of 50.0% vs 30.6% with ML protocol (P=0.022)
- Pregnancy outcomes equivalent to patients with normal endometrium 4
The EL protocol was an independent factor affecting both clinical pregnancy (adjusted OR 2.479) and live birth (adjusted OR 2.730) 4.
Key Clinical Pitfalls to Avoid
- Do not proceed with embryo transfer before documenting complete regression - this risks implantation into abnormal endometrium
- Do not delay embryo transfer after achieving regression - prolonged waiting increases recurrence risk from endogenous estrogen
- Do not use the midluteal long protocol - it yields significantly inferior pregnancy outcomes in this population 4
- Do not consider hysterectomy - it is not indicated for hyperplasia without atypia, especially in fertility-seeking patients 1
Long-Term Follow-Up
After successful pregnancy and delivery, continue long-term surveillance as these patients remain at risk for recurrence 1. Patient education about medication adherence and symptom monitoring is essential for preventing progression 1.
The evidence strongly supports that hyperplasia without atypia has minimal risk of progression to cancer (unlike atypical hyperplasia which carries ~20% progression risk 5), making conservative fertility-preserving treatment entirely appropriate in this clinical scenario.